Charles River Laboratories (CRL) balance sheet and financial health

Life Sciences Tools & Services · NYSE · Health Care

$332.16 -1.00% Close Nov 17, 2026 Live

TrendArc score 45 of 100 · Health 4.5 · Momentum 8.4 · Moat 5.0 · scored Nov 17, 2026 · How the score works

Cash and short-term investments less borrowings, September 26, 2026

$2.2 billion more borrowings than cash

Charles River Laboratories held $200 million of cash and short-term investments against $2.4 billion of borrowings on September 26, 2026. In the fiscal year to December 2025 its operating income covered its interest 0.2 times.

Borrowings to equity

0.76

$2.44B of borrowings on $3.23B of equity, Sep 2026

Interest cover

0.2x

operating income over interest, fiscal year to December 2025

Return on invested capital

21.9%

latest quarter to September 2026, annualised; the stock card's measure

Cash and borrowings at each fiscal year end

$1.00B$2.00B$3.00B2016201720182019202020212022202320242025Cash and short-terminvestments $214MBorrowings $2.11B$1.00B$2.00B$3.00B20172019202120232025Cash and short-term investments $214MBorrowings $2.11B

What the balance sheet holdsSeptember 26, 2026

Assets $7.45BSmaller items: long-term investments $195MCash and short-term investments$200MReceivables$735MInventory$320MOther current assets$280MProperty, goodwill and other$5.72BFunded by $7.45BBorrowings$2.44BOther liabilities$1.74BMinority interests and other$48.3MShareholders' equity$3.23BAssets $7.45BCash and short-term investments$200MReceivables$735MInventory$320MOther current assets$280MLong-term investments$195MProperty, goodwill and other$5.72BFunded by $7.45BBorrowings$2.44BOther liabilities$1.74BMinority interests and other$48.3MShareholders' equity$3.23B

"Other liabilities" is total liabilities less borrowings; "Property, goodwill and other" is total assets less the current assets and long-term investments; "Minority interests and other" is the rest of the funding (total assets less liabilities and shareholders' equity), mostly outside owners' stakes in subsidiaries.

Balance sheet, the last 10 fiscal year ends

In billions of US dollars, at each fiscal year end, named by the month it ended; the first column is the newest balance sheet on file. Borrowings are bonds, notes, loans and commercial paper; lease liabilities, operating and finance, are shown apart.
Fiscal year endLatest
Sep 2026
Dec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
Assets
Cash and short-term investments0.200.210.190.280.230.240.230.240.200.160.12
Receivables0.740.710.720.780.750.640.620.510.470.430.36
Inventory0.320.300.280.380.260.200.190.160.130.110.10
Other current assets0.280.230.210.170.200.190.170.110.100.120.08
Total current assets1.541.451.401.611.441.271.201.020.900.830.66
Long-term investments0.190.210.220.240.310.200.000.000.000.000.00
Total assets7.457.147.538.207.607.025.494.693.862.932.71
Liabilities and equity
Current liabilities1.091.120.991.061.091.030.840.710.560.460.43
Borrowings2.442.112.212.622.682.641.951.861.671.151.24
Lease liabilities—0.520.570.500.470.310.210.17———
Total liabilities4.183.924.024.544.584.433.353.032.521.871.86
Minority interests and other0.050.050.050.060.050.060.030.030.020.020.02
Shareholders' equity3.233.163.463.602.982.532.111.631.321.050.84
Financial health
Cash less borrowings-2.24-1.90-2.02-2.35-2.45-2.40-1.72-1.62-1.47-0.98-1.12
Borrowings to equity0.760.670.640.730.901.040.921.141.271.101.48
Interest cover—0.2x1.8x4.5x11.0x8.0x5.0x5.8x5.2x9.7x8.6x

Interest cover is operating income over interest expense, for full fiscal years. Minority interests and other is total assets less total liabilities and shareholders' equity (calculated by TrendArc). Company filings as standardised by Tiingo; borrowings and lease liabilities told apart with the lines the company files on SEC EDGAR, and a dash where the two cannot be told apart. Rebuilt nightly.

Charles River Laboratories against its peers

CompanyCash less borrowingsBorrowings to equityInterest coverReturn on invested capital
Bio-TechneTECH +$150M 0.09 26.2x 5.1%
IlluminaILMN -$452M 0.57 8.0x 16.4%
Mettler ToledoMTD -$1.97B 26.06 16.1x 48.2%
Agilent TechnologiesA -$2.19B 0.54 13.2x 13.2%
Charles River LaboratoriesCRL -$2.24B 0.76 0.2x 21.9%
WatersWAT -$4.54B 0.34 11.5x 1.6%
IQVIAIQV -$13.6B 2.41 3.0x 6.4%

Each company's newest balance sheet; borrowings leave lease liabilities out; interest cover for its newest fiscal year; return on invested capital is the stock card's measure. A dash where a measure does not apply.

Next

Follow Charles River Laboratories with a free account.

A watchlist, price alerts and saved chart layouts. No card needed.

Sign up free

No forecast, no recommendation. This page describes Charles River Laboratories from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.

The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.